Alphabet’s life sciences subsidiary Verily is ending its medical device program and cutting staff as the company redirects more resources to AI, TechCrunch reported Aug. 26.
Here are three things to know:
- The decision was announced in a staff memo on Aug. 25 by Verily CEO Stephen Gillett. This memo was first reported by Business Insider.
- Mr. Gillett said the program had produced “world-class, innovative medical devices” but that the company’s future depends on a greater focus on AI and data infrastructure.
- The restructuring aligns with Alphabet’s broader push to cut costs while expanding its AI capabilities. The tech giant has conducted multiple rounds of layoffs in recent years, including reductions in its human resources and cloud units earlier this year.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
